The legislature's own summary of the bill, or its official long title.
Relating to the establishment of a consortium to conduct United States Food and Drug Administration's drug development clinical trials with ibogaine to secure the administration's approval of the medication's use for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy and to the administration of that treatment.
Every action
73 steps, oldest first, as the legislature records them.
Show the 65 earlier steps
SenateReceived by the Secretary of the Senate
SenateFiled
SenateRead first time
SenateReferred to Health & Human Services
CommitteeScheduled for public hearing on . . . · Senate Health & Human Services
CommitteeConsidered in public hearing · Senate Health & Human Services
CommitteeTestimony taken in committee · Senate Health & Human Services
CommitteeLeft pending in committee · Senate Health & Human Services
CommitteeConsidered in public hearing · Senate Health & Human Services
CommitteeVote taken in committee · Senate Health & Human Services
CommitteeReported favorably w/o amendments · Senate Health & Human Services
SenateCommittee report printed and distributed
SenateCo-author authorized
SenatePlaced on intent calendar
SenateRules suspended-Regular order of business
SenateRecord vote
SenateRead 2nd time & passed to engrossment
SenateRecord vote
SenateThree day rule suspended
SenateRecord vote
SenateRead 3rd time
SenatePassed
SenateRecord vote
SenateReported engrossed
HouseReceived from the Senate
HouseRead first time
CommitteeReferred to Public Health · House Public Health
CommitteeConsidered in formal meeting · House Public Health
CommitteeCommittee substitute considered in committee · House Public Health
CommitteeReported favorably as substituted · House Public Health
HouseComte report filed with Committee Coordinator
HouseHouse grants request for conference committee
HouseHouse appoints conferees
SenateHouse grants request for conf comm-reported
SenateHouse appoints conferees-reported
SenateConference committee report filed
HouseConf. Comm. Report distributed
SenateSenate adopts resolution to go outside bounds (SR 703)
SenateSenate adopts conference committee report
SenateRecord vote
HouseSenate adopts conf. comm. report-reported
HouseHouse adopts resolution to go outside bounds (HR 1495)
HouseHouse adopts conference committee report
HouseRecord vote (RV#4133)
HouseStatement(s) of vote recorded in Journal
SenateHouse adopts conf. comm. report-reported
SenateReported enrolled
SenateSigned in the Senate
HouseSigned in the House
GovernorSent to the Governor
GovernorSigned by the Governor
GovernorEffective immediately
Roll calls
10 recorded votes: 8 on the floor, 2 in committee. Each shows how every member voted.
Senator Parker moved that Senate Rule 7.18 and the Constitutional Rule requiring bills to be read on three several days be suspended and that SB 2308 be placed on its third reading and final passage. — The motion prevailed · Full Senate
Representative Bonnen moved to adopt the conference committee report on SB 2308 . — The motion to adopt the conference committee report on SB 2308 prevailed · Full House
Health & Human Services: Reported favorably w/o amendments
Passed 8–0
Apr 30, 2025
Full Senate
SB 2308 , Relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine for the purpose of securing the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy a — The motion prevailed Members